Naoshi Nishida

28PUBLICATIONS
60CO-AUTHORS
Predictive and prognostic markersOncology and carcinogenesis not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)Artificial life and complex adaptive systemsLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Jan 25, 2026
Impact of Early-Line Systemic Therapies on Liver Function in Hepatocellular Carcinoma: Longitudinal Change of ALBI Score and Ammonia Level With and Without Anti-VEGF Agents.

Naoshi Nishida, Kazuomi Ueshima, Tomoko Aoki

|Dec 11, 2025
No Correlation Between Proteinuria and Renal Function in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: ARISE Study.

Kazuomi Ueshima, Naoshi Nishida, Satoru Hagiwara

|Apr 14, 2025
Biomarkers and Management of Cholangiocarcinoma: Unveiling New Horizons for Precision Therapy.

Naoshi Nishida

|Mar 07, 2025
Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study.

Tomoko Aoki, Masatoshi Kudo, Naoshi Nishida

|Jan 08, 2025
Advancements in Artificial Intelligence-Enhanced Imaging Diagnostics for the Management of Liver Disease-Applications and Challenges in Personalized Care.

Naoshi Nishida

|Nov 23, 2023
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.

Federico Rossari, Toshifumi Tada, Goki Suda

Pageof 5

Frequent Collaborators

17 joint publications

Masatoshi Kudo

8 joint publications

Yasunori Minami

8 joint publications

Tomoko Aoki

3 joint publications

Kosuke Minaga